文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

[161Tb]Tb-PSMA-617 放射性配体治疗 mCRPC 的器官与肿瘤剂量学

Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-09-08

本研究纳入 15 例转移性去势抵抗性前列腺癌(mCRPC)患者,接受 [161Tb]Tb-PSMA-617 治疗,中位 2 个周期,平均给药活度 6.0 ± 1.3 GBq,平均累积活度 12.3 ± 4.6 GBq。采用全身平面显像与 SPECT/CT 混合剂量学评估危险器官及肿瘤吸收剂量。结果显示肿瘤平均吸收剂量 5.95 ± 3.60 Gy/GBq,肿瘤/肾脏与肿瘤/腮腺比值分别为 10.55 ± 8.32 和 16.15 ± 11.85,提示该核素在 PSMA 靶向治疗中具有良好剂量学特征。

要点

  • 肾脏平均吸收剂量 0.70 ± 0.41 Gy/GBq,腮腺 0.40 ± 0.20 Gy/GBq,下颌下腺 0.36 ± 0.14 Gy/GBq,肝脏 0.13 ± 0.08 Gy/GBq。
  • 43 个肿瘤病灶平均总体吸收剂量 5.95 ± 3.60 Gy/GBq,平均半衰期 44.07 h ± 15.88 h。
  • 肿瘤/肾脏与肿瘤/腮腺吸收剂量比分别为 10.55 ± 8.32 和 16.15 ± 11.85。

核心结论

  • [161Tb]Tb-PSMA-617 可向肿瘤递送较高吸收剂量,同时危险器官剂量可耐受,肿瘤/正常器官比值有利。
  • 剂量学结果支持 161Tb 作为 mCRPC 中 PSMA 靶向放射性配体治疗的有前景核素。

研究设计与样本

  • 研究纳入 15 例参加注册研究(NCT04833517)并接受 [161Tb]Tb-PSMA-617 治疗的 mCRPC 患者。
  • 患者接受中位 2 个周期(范围 1–3)治疗,平均给药活度 6.0 ± 1.3 GBq,平均累积活度 12.3 ± 4.6 GBq。
  • 采用全身平面显像与 SPECT/CT 混合剂量学分析危险器官(唾液腺、肾脏、肝脏)及肿瘤病灶,使用 OLINDA/EXM 估算 161Tb 吸收剂量。

主要发现

  • 肾脏、腮腺、下颌下腺和肝脏平均吸收剂量分别为 0.70 ± 0.41、0.40 ± 0.20、0.36 ± 0.14 和 0.13 ± 0.08 Gy/GBq。
  • 43 个病灶的肿瘤动力学显示活度随时间稳定,所有病灶平均半衰期为 44.07 h ± 15.88 h。
  • 肿瘤平均总体吸收剂量为 5.95 ± 3.60 Gy/GBq,肿瘤/肾脏和肿瘤/腮腺吸收剂量比分别为 10.55 ± 8.32 和 16.15 ± 11.85。

临床怎么用

  • 基于混合剂量学可评估 [161Tb]Tb-PSMA-617 治疗中危险器官与肿瘤病灶的吸收剂量。
  • 较高的肿瘤/肾脏与肿瘤/腮腺吸收剂量比支持在 mCRPC 中进一步评估该核素的 PSMA 靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Terbium-161 (161Tb) has emerged as a promising radionuclide for radioligand therapy (RLT) due to its emission of Auger and conversion electrons, which may support therapeutic efficacy through increased local energy deposition. Despite growing research efforts aimed at the clinical potential of 161Tb, dosimetric data, particularly for tumor lesions, remain scarce. To address this gap, we assessed tumor and organ dosimetry in mCRPC patients treated with [161Tb]Tb-PSMA-617. METHODS: The study involved n = 15 patients with metastasized castration-resistant prostate cancer (mCRPC) participating in a registry (NCT04833517) and receiving [161Tb]Tb-PSMA-617. All patients received a median of 2 (range: 1-3) cycles with mean administered activity of 6.0 ± 1.3 GBq and mean cumulative activity of 12.3 ± 4.6 GBq [161Tb]Tb-PSMA-617. Hybrid dosimetry of organs at risk, including the salivary glands, the kidneys, the liver, and tumor lesions was performed analyzing whole-body planar and SPECT/CT images. Absorbed doses were estimated using OLINDA/EXM for 161Tb. Tumor-to-organ ratios (TR) of mean tumor-absorbed doses over relevant organs at risk were calculated. RESULTS: Mean absorbed dose to kidneys, parotid glands, submandibular glands and liver was 0.70 ± 0.41 Gy/GBq, 0.40 ± 0.20 Gy/GBq, 0.36 ± 0.14 Gy/GBq and 0.13 ± 0.08 Gy/GBq, respectively. Tumor kinetics in 43 lesions demonstrated stable activity over time (mean half-life of all lesions: 44.07 h ± 15.88 h) delivering a mean overall absorbed tumor dose of 5.95 ± 3.60 Gy/GBq, the resulting TR over kidney and parotid gland were 10.55 ± 8.32 and 16.15 ± 11.85, respectively. CONCLUSION: [161Tb]Tb-PSMA-617 delivers high tumor-absorbed doses with tolerable doses to relevant organs at risk, translating into favorable tumor-to-normal-organ ratios. Dosimetry results confirm 161Tb as a promising radionuclide for PSMA-targeted radioligand therapy in mCRPC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Schaefer-Schuler A, Blickle A, Ganz S, et al. Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2026. PMID: 42709069. doi:10.1007/s00259-026-08171-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。